Recently, the Category I innovative drug Entinostat Tablets (Chinese trade name: 景助达) of Taizhou EOC Pharma Co. Ltd was approved for marketing by the National Medical Products Administration. The drug is used in combination with an aromatase inhibitor for the treatment of patients with locally advanced or metastatic breast cancer who are hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER-2) negative after endocrine therapy.

Entestat tablet is a histone deacetylase (HDAC) inhibitor, which can selectively inhibit class I and IV HDACs, inhibit cell proliferation, promote terminal differentiation and/or induce apoptosis, and exert antitumor effects. The marketing of this drug provides a new treatment option for patients with locally advanced or metastatic breast cancer who are hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER-2) negative.